



ASIAN HEALTHCARE SPECIALISTS LIMITED

FOR IMMEDIATE RELEASE

Asian Healthcare Specialists records 62.8% revenue growth to S\$27.6 million and net profit growth of 73.2% to S\$4.5 million in FY2021

SINGAPORE, 26 November 2021 – Asian Healthcare Specialists Limited (“Asian Healthcare Specialists”), together with its subsidiaries, “**Group**” (SGX: 1J3.SI; Bloomberg quote: AHSP:SP), a multi-disciplinary medical services group with an experienced group of medical specialists and doctors that engages in the provision of a wide range of general and specialised healthcare services, comprising of anaesthesia, dermatology, family medicine, gastroenterology, orthopaedics, ophthalmology, otorhinolaryngology (“**ENT**”), urology and rehabilitative services, announced today its unaudited financial results for the half year ended 30 September 2021 (“**2H2021**”) and the full year ended 30 September 2021 (“**FY2021**”).

Financial Highlights (S\$'000)	2H2021	2H2020	Change (%)
Revenue	14,214	10,246	38.7%
Net profit attributable to owners of the Company	2,448	1,565	56.4%

Financial Highlights (S\$'000)	FY2021	FY2020	Change (%)
Revenue	27,563	16,934	62.8%
Net profit attributable to owners of the Company	4,476	2,585	73.2%

The Group’s revenue increased by S\$10.6 million or 62.8%, to S\$27.6 million in FY2021. The increase was mainly due to the consolidation of the results of Cornerstone Asia Health Pte. Ltd. (“**CAH**”), pursuant to the Company’s acquisition of 51.0% of CAH in February 2020. In FY2021, CAH contributed S\$13.7 million (FY2020: S\$6.7 million) to the Group’s revenue. The revenue growth in FY2021 was also attributed to the increase in the number of patient visits as compared to last year pursuant to the recovery from the COVID-19 pandemic, and the commencement of operation of ENT clinic in November 2020.

The Group’s net profit attributable to owners of the Company increased by \$1.9 million or 73.2% in FY2021. The increase was in tandem with the increase in revenue.

“Being a medical professional myself, I understand the pressures and challenges of the profession and I would therefore like to extend my personal heartfelt thanks to each and every colleague for the unselfish dedication, commitment and courage in going beyond the call of duty”, comments Dr Chin Pak Lin, Chief Executive Officer.

On behalf of the Board of Directors (“**Board**”), we would like to extend our sincere appreciation to our shareholders, business partners and all our stakeholders for their dedication and unwavering support over the past years and look towards the years ahead as we continue to be at the frontline of positive change and a leading provider of holistic medical care with a focus of medical excellence and ethics.

In view of rewarding shareholders for their support, the Board is pleased to propose a final one-tier exempt dividend of S\$0.0028 per share in respect of FY2021, subject to the shareholders’ approval at the upcoming Annual General Meeting. Together with the interim dividend payment of S\$0.0042 per share declared on 14 May 2021, the total dividend payment will be S\$0.007 per share for FY2021.

~~ End ~~

About Asian Healthcare Specialists Limited

We are a multi-disciplinary medical services group with an experienced group of medical specialists and doctors that engages in the provision of a wide range of general and specialized healthcare services, comprising of anaesthesia, dermatology, family medicine, gastroenterology, orthopaedics, ophthalmology, otorhinolaryngology, urology and rehabilitative services. The Group aims to provide a more comprehensive suite of in-house services to patients who have more complex medical issues requiring input from various specialties.



Asian Healthcare Specialists Limited and its subsidiaries (collectively, the “**Group**”) currently have 14 medical specialists and doctors operating at 12 clinics at convenient and accessible locations across Singapore.

For Investor Relations related queries, please contact:

Mr Travis Seet
Chief Financial Officer
(65) 6581 7388
travis.seet@toc.com.sg

*This press release has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, RHT Capital Pte. Ltd. (the “**Sponsor**”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”). The Sponsor has not independently verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mah How Soon - Registered Professional, 6 Raffles Quay, #24-02, Singapore 048580, sponsor@rhtgoc.com